Two deaths involving children in separate experimental genetic-treatment studies have intensified scrutiny of how first-in-human and investigator-initiated trials are governed in China. The cases involve different diseases, technologies and research teams, so they should not be treated as evidence that gene therapy as a whole is unsafe. Together, however, they raise difficult questions about risk assessment, disclosure and oversight when experimental treatments move rapidly from laboratory work into children.
The first case involved a six-year-old girl, identified publicly by the pseudonym Mei, who had Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder. She received a bespoke brain-directed gene-editing treatment in Shanghai in March 2025 and died within days. Reporting by Science and Chinese media described a severe treatment-associated reaction and prompted an investigation by Shanghai Jiao Tong University. The case drew particular concern because the death had not been publicly disclosed alongside related research.
A second case was disclosed by HuidaGene Therapeutics in August 2026. The company said that a participant in the high-dose cohort of HG302-01, a first-in-human investigator-initiated trial of an experimental gene-editing therapy for Duchenne muscular dystrophy, died after receiving treatment in August 2025. HuidaGene described the event as a fatal serious adverse event and said it undertook clinical, immunological, pathological and post-mortem analyses.
Gene editing and gene therapy cover many different technologies. Some modify DNA directly; others deliver functional genes without changing the genome. Delivery systems can include viral vectors, lipid nanoparticles or engineered cells. Risks vary by target organ, dose, vector, immune response and disease. That is why a safety problem in one program cannot simply be generalized to another.
The ethical stakes are particularly high in pediatric first-in-human research. Children may have severe diseases with few options, but they also cannot provide adult informed consent and may face lifelong consequences from an irreversible intervention. For disorders that are debilitating but not immediately fatal, investigators must justify why uncertain experimental risk is proportionate to the expected benefit.
The two cases also highlight the role of transparency. Serious adverse events are essential information for other researchers designing related trials, for regulators assessing class-wide risks and for families deciding whether to participate. Delayed or incomplete disclosure can weaken the collective safety system even when the underlying biological cause is unique to one program.
China has become one of the world's fastest-moving centers for gene and cell therapy. The next phase of that growth will depend not only on technical success but on whether oversight keeps pace with experimentation. These deaths are likely to sharpen pressure for clearer reporting rules, independent review and consistent safety standards across investigator-initiated studies.